Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Early Stage Triple Negative ER Low Breast Cancer 1

Interventions

Specimen Handling 276 pembrolizumab 227 Magnetic Resonance Spectroscopy 226 Carboplatin 180 Cisplatin 166 Biopsy 166 Nivolumab 158 Cyclophosphamide 144 Radiotherapy 125 Paclitaxel 124 Gemcitabine 116 Bevacizumab 95 durvalumab 92 Dexamethasone 88 Rituximab 81 Oxaliplatin 80 venetoclax 75 atezolizumab 71 Fluorouracil 70 Docetaxel 70 Capecitabine 70 Doxorubicin 68 Etoposide 65 Radiosurgery 64 Ipilimumab 63 Radiation 61 Prednisone 60 Cytarabine 60 Lenalidomide 58 Pemetrexed 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Interleukin 1 Receptor Antagonist Protein × 90 days × Clear all

NCT06710197 2026-03-05

OZM-034

University Health Network, Toronto

Phase 2 Withdrawn

Early Stage Triple Negative ER Low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡